

WINDLAS BIOTECH LIMITED

CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT

Product Name	HEALMARYL MV 2.3 TABLETS		
Generic Name/Dosage Form Strength (mg)	Glimepiride 2 mg, Voglibose 0.3 mg & Metformin Hydrochloride (SR) 500 mg Tablets		
Batch No.	HMK24001	A.R. No.	QC/FG/24/01611
Batch Size	200000 TABLET	Pack Size	10 X 10 TABLET
Mfg. Date	02/2024	Exp. Date	01/2026
Reference	IH	Market	Domestic
Sample Received on	15/02/2024	Sample Qty.	1x125 TABLET
Ref. STP No.	WBL/STP/FG/0282	Ref. SPS No.	WBL/FPS/FG/5798
Date of Analysis started on	17/02/2024	Date of Analysis completed on	14/03/2024
Page No.	01 of 03		

S.No.	Test	Specification	Result
1	Description	Light brown & White to off white coloured, elongated, biconvex, bilayered, uncoated tablet, plain on both sides.	Light brown & White coloured, elongated, biconvex, bilayered, uncoated tablet, plain on both sides.
2	Identification		
2a.	For Glimepiride & Voglibose	The retention time of the principal peak in the chromatogram of Sample Solution corresponds to that the Standard Solution obtained as directed in the Assay.	Complies
2b.	For Metformin Hydrochloride	When examined in the range of 200-300 nm, a 0.001 per cent w/v solution of Metformin Hydrochloride RS and Test Solution, as obtained in the Assay, shows absorption maxima, at about 232 nm.	Complies
3	Friability	Not more than 1.0% w/w	0.15 % w/w
4	Average weight	800.25 to 849.75 mg	829.99 mg
5	Uniformity of weight	Not more than 2 tablets in 20 deviates from the average weight by more than 5%. No tablet deviate from the average weight by more than 10%.	-1.07% to + 1.34%
6	Dissolution		

	Prepared By-QC	Checked By-QC	Reviewed By-Lab.-QA	Approved By-Head-QC/Designee
Name	Vandana Benwal	Rakesh Kumar	Lakshay	Jogendra Singh
Designation	TRAINEE CHEMIST	Sr. Executive	Assistant Manager-QA	G. M.
Date	14/03/2024	14/03/2024	14/03/2024	14/03/2024

Printed By: Shubham Pal

Date & Time : 16/03/2024 4:15:11 PM

Copy No. 2

This is a electronically signed document, hence does not require any signatures

Format No. : QC/CM/013/F/12-01

WINDLAS BIOTECH LIMITED

CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT

Product Name	HEALMARYL MV 2.3 TABLETS		
Generic Name/Dosage Form Strength (mg)	Glimepiride 2 mg, Voglibose 0.3 mg & Metformin Hydrochloride (SR) 500 mg Tablets		
Batch No.	HMK24001	A.R. No.	QC/FG/24/01611
Batch Size	200000 TABLET	Pack Size	10 X 10 TABLET
Mfg. Date	02/2024	Exp. Date	01/2026
Reference	IH	Market	Domestic
Sample Received on	15/02/2024	Sample Qty.	1x125 TABLET
Ref. STP No.	WBL/STP/FG/0282	Ref. SPS No.	WBL/FPS/FG/5798
Date of Analysis started on	17/02/2024	Date of Analysis completed on	14/03/2024
Page No.	02 of 03		

S.No.	Test	Specification	Result
6a.	1st hour Metformin Hydrochloride IP	25.0 to 50.0%	Min-32.6% Max-36.2% Avg-34.3%
6b.	3rd hour Metformin Hydrochloride IP	45.0 to 75.0%	Min-63.6% Max-67.1% Avg-65.3%
6c.	10th hour Metformin Hydrochloride IP	Not less than 80.0%	Min-100.0% Max-102.7% Avg-101.4%
6d.	Dissolution Glimepiride IP	Not less than 70.0% of labeled amount	Min-99.0% Max-100.4% Avg-99.6%
7	Uniformity of Dosage Units		
7a.	(By Content Uniformity) Glimepiride IP	Acceptance value should be less than 15	11.10
7b.	(By Content Uniformity) Voglibose IP	Acceptance value should be less than 15	5.64
7c.	(By Weight Variation) Metformin Hydrochloride IP	Acceptance value should be less than 15	2.00
8	Assay Each uncoated bilayered tablet contains:		
8a.	Glimepiride IP...2mg	90.0 to 110.0%	103.5%
8b.	Voglibose IP...0.3mg	90.0 to 110.0%	100.7%

	Prepared By-QC	Checked By-QC	Reviewed By-Lab.-QA	Approved By-Head-QC/Designee
Name	Vandana Benwal	Rakesh Kumar	Lakshay	Jogendra Singh
Designation	TRAINEE CHEMIST	Sr. Executive	Assistant Manager-QA	G. M.
Date	14/03/2024	14/03/2024	14/03/2024	14/03/2024

Printed By: Shubham Pal

Date & Time : 16/03/2024 4:15:11 PM

Copy No. 2

This is a electronically signed document, hence does not require any signatures

Format No. : QC/CM/013/F/12-01

WINDLAS BIOTECH LIMITED

CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT

Product Name	HEALMARYL MV 2.3 TABLETS		
Generic Name/Dosage Form Strength (mg)	Glimepiride 2 mg, Voglibose 0.3 mg & Metformin Hydrochloride (SR) 500 mg Tablets		
Batch No.	HMK24001	A.R. No.	QC/FG/24/01611
Batch Size	200000 TABLET	Pack Size	10 X 10 TABLET
Mfg. Date	02/2024	Exp. Date	01/2026
Reference	IH	Market	Domestic
Sample Received on	15/02/2024	Sample Qty.	1x125 TABLET
Ref. STP No.	WBL/STP/FG/0282	Ref. SPS No.	WBL/FPS/FG/5798
Date of Analysis started on	17/02/2024	Date of Analysis completed on	14/03/2024
Page No.	03 of 03		

S.No.	Test	Specification	Result
8c.	Metformin Hydrochloride IP (as sustained release form)...500mg	90.0 to 110.0%	100.8%

Remarks : In the opinion of undersigned the sample refer to above specifications complies with IH

	Prepared By-QC	Checked By-QC	Reviewed By-Lab.-QA	Approved By-Head-QC/Designee
Name	Vandana Benwal	Rakesh Kumar	Lakshay	Jogendra Singh
Designation	TRAINEE CHEMIST	Sr. Executive	Assistant Manager-QA	G. M.
Date	14/03/2024	14/03/2024	14/03/2024	14/03/2024

Printed By: Shubham Pal

Date & Time : 16/03/2024 4:15:11 PM

Copy No. 2

This is a electronically signed document, hence does not require any signatures

Format No. : QC/CM/013/F/12-01